DE3683479D1 - Loesliches phosphoryliertes glukan. - Google Patents

Loesliches phosphoryliertes glukan.

Info

Publication number
DE3683479D1
DE3683479D1 DE8686905497T DE3683479T DE3683479D1 DE 3683479 D1 DE3683479 D1 DE 3683479D1 DE 8686905497 T DE8686905497 T DE 8686905497T DE 3683479 T DE3683479 T DE 3683479T DE 3683479 D1 DE3683479 D1 DE 3683479D1
Authority
DE
Germany
Prior art keywords
soluble phosphorylated
useful
glucans
soluble
phosphorylated glucan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686905497T
Other languages
English (en)
Inventor
R Diluzio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Application granted granted Critical
Publication of DE3683479D1 publication Critical patent/DE3683479D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE8686905497T 1985-08-19 1986-08-13 Loesliches phosphoryliertes glukan. Expired - Lifetime DE3683479D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/767,388 US4739046A (en) 1985-08-19 1985-08-19 Soluble phosphorylated glucan
PCT/US1986/001646 WO1987001037A1 (en) 1985-08-19 1986-08-13 Soluble phosphorylated glucan

Publications (1)

Publication Number Publication Date
DE3683479D1 true DE3683479D1 (de) 1992-02-27

Family

ID=25079320

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686905497T Expired - Lifetime DE3683479D1 (de) 1985-08-19 1986-08-13 Loesliches phosphoryliertes glukan.

Country Status (12)

Country Link
US (5) US4739046A (de)
EP (1) EP0232405B1 (de)
JP (1) JP2550332B2 (de)
KR (1) KR900008442B1 (de)
AT (1) ATE71528T1 (de)
AU (1) AU599045B2 (de)
CA (1) CA1337408C (de)
DE (1) DE3683479D1 (de)
DK (1) DK198587A (de)
FI (1) FI88109C (de)
NO (1) NO170586C (de)
WO (1) WO1987001037A1 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082936A (en) * 1984-11-28 1992-01-21 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) * 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4992540A (en) * 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US4975421A (en) * 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing
JPH02502335A (ja) * 1987-02-26 1990-08-02 バイオ　ポリマーズ　プロプライエタリー　リミテッド 植物ガム物質および食品への使用
AU599241B2 (en) * 1987-06-18 1990-07-12 Kureha Kagaku Kogyo Kabushiki Kaisha Polysaccharides and antiviral drugs containing the same as active ingredient
US4904768A (en) * 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
RU2092183C1 (ru) * 1988-05-26 1997-10-10 Ника Хелт Продактс Лимитед (Лихтенштейн) Антивирусный или антибактериальный состав и способ его употребления
ATE139699T1 (de) * 1988-08-19 1996-07-15 Univ Australian Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel
US5506210A (en) * 1988-08-19 1996-04-09 The Australian National University Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
US6747131B1 (en) 1988-10-28 2004-06-08 Pestka Biomedical Laboratories, Inc. Phosphorylated fusion proteins
US5986061A (en) 1988-10-28 1999-11-16 Pbl Biomedical Laboratories Phosphorylated fusion proteins
IL92124A (en) 1988-10-28 1996-10-31 Sidney Pestka Recombinant proteins modified to contain post-phosphorylation that do not occur in nature
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
JP2984366B2 (ja) * 1989-04-05 1999-11-29 バイオミラ、インコーポレーテッド 免疫抑制ムチンを生成する腺がんの能動的特異免疫療法
US4946450A (en) * 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
FR2648350B1 (fr) * 1989-06-20 1994-07-01 Roussel Uclaf Utilisation de lipopolysaccharides extraits de bacteries gram(-) pour la fabrication d'un medicament facilitant la cicatrisation de la peau
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
WO1991003495A1 (en) * 1989-09-08 1991-03-21 Alpha Beta Technology, Inc. Method for producing soluble glucans
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
CA2067159A1 (en) * 1989-09-08 1991-03-09 Spiros Jamas Method for immune system activation
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5223491A (en) * 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
FR2655267B1 (fr) * 1989-12-04 1992-04-03 Roussel Uclaf Nouveau derive sulfate du galactanne extrait de klebsiella, procede de preparation, application a titre de medicaments et compositions pharmaceutiques le renfermant.
US5242806A (en) * 1990-05-07 1993-09-07 Baxter Diagnostics Inc. Method for conducting the cytotoxicity assays on tumor cells
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
ES2027528A6 (es) * 1990-12-17 1992-06-01 Andromaco Lab Procedimiento para la obtencion de polimeros con actividad antiviral.
DE4101910A1 (de) * 1991-01-23 1992-07-30 Laevosan Gmbh & Co Kg Verfahren zur herstellung eines pyrogenfreien gut wasserloeslichen fructans sowie ein nierendiagnostikum, das ein solches fructan enthaelt
AU1455292A (en) * 1991-02-01 1992-09-07 Bioglucans, L.P. Soluble glucans
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
PL173978B1 (pl) * 1992-07-13 1998-05-29 Nika Health Products Ltd Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
AU4837693A (en) * 1992-08-05 1994-03-03 Bioglucans, L.P. Improved method for preparing soluble glucans
EP0595209A3 (en) * 1992-10-23 1996-07-17 R I T A Corp An Illinois Corp Cosmetic composition
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
US5519009A (en) * 1993-10-01 1996-05-21 Donzis; Byron A. Solubilized yeast glucan
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
JP3240102B2 (ja) 1994-08-11 2001-12-17 江崎グリコ株式会社 リン酸化糖とその製造方法
US5576015A (en) * 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
GB2331014C (en) * 1995-03-13 2005-06-21 Novogen Res Pty Ltd Therapeutic uses of glucan
US5833946A (en) * 1995-06-06 1998-11-10 Bayer Corporation Dissemination of fungal infections: animal model and method of prophylaxis
US6800747B1 (en) 1995-06-07 2004-10-05 Pestka Biomedical Laboratories, Inc. Nucleic acids encoding phosphorylated fusion proteins
US6117850A (en) * 1995-08-28 2000-09-12 The Collaborative Group, Ltd. Mobilization of peripheral blood precursor cells by β(1,3)-glucan
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
EP0954283B1 (de) 1996-12-30 2007-03-21 Battelle Memorial Institute Verwendung eines unverkapselten anti-krebs-wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
DE19710368A1 (de) * 1997-03-13 1998-09-17 Henkel Kgaa Verwendung von wasserlöslichen beta-Glucanen als Wirkstoffe zur Herstellung von therapeutischen Mitteln zur Hautbehandlung
US6046323A (en) * 1997-07-29 2000-04-04 The Collaborative Group, Ltd. Conformations of PPG-glucan
IL135148A0 (en) * 1997-10-03 2001-05-20 Galenica Pharmaceuticals Inc A polysaccharide conjugate and pharmaceutical compositions containing the same
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US6251877B1 (en) * 1998-03-24 2001-06-26 Pacific Corporation Composition for external application containing a β-1,6-branched-β-1,3-glucan
JP2002513028A (ja) 1998-04-28 2002-05-08 ガレニカ ファーマシューティカルズ， インコーポレイテッド ポリサッカリド抗原結合体
TW591105B (en) * 1998-04-30 2004-06-11 Korea Inst Sci & Tech Novel immuno-stimulating polysaccharide substance from Phellinus spp. strain and use thereof
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
EP1121135B1 (de) * 1998-09-14 2009-01-28 Nabi Biopharmaceuticals Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
AU6261999A (en) * 1998-09-25 2000-04-17 Collaborative Group, Ltd., The Very high molecular weight beta-glucans
US6369216B1 (en) 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
AUPP659198A0 (en) * 1998-10-19 1998-11-12 Novogen Research Pty Ltd Mastitis treatment
US6165994A (en) * 1999-02-08 2000-12-26 Blue Ridge Pharmaceuticals, Inc. Methods for promoting the healing of cutaneous wounds and ulcers using compositions of α-D-glucans
US7101544B1 (en) 1999-07-21 2006-09-05 Kabushiki Kaisha Yakult Honsha Cholesterol-lowering agents, secondary bile acid production inhibitors, and foods and drinks
US6541678B2 (en) * 1999-09-27 2003-04-01 Brennen Medical, Inc. Immunostimulating coating for surgical devices
EP1267795A1 (de) * 2000-03-30 2003-01-02 Brennen Medical Inc. Antimikrobielle und immunstimulierende zusammensetzung
US6713459B1 (en) 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
JP2001354570A (ja) * 2000-06-15 2001-12-25 Ichimaru Pharcos Co Ltd 免疫賦活剤及びそれを利用した香粧品
BR0114713A (pt) * 2000-10-16 2004-01-13 Neopharm Inc Formulação lipossÈmica de mitoxantrona
US6436411B1 (en) * 2000-10-23 2002-08-20 The Center For The Improvement Of Human Functioning, Int'l., Inc. Cancer treatment method
DE60018812T2 (de) * 2000-11-22 2005-08-11 D.M.G. Italia Srl Arzneizubereitung zur intranasalen verabreichung um die immunantwort in der mund- und nasenschleimhaut und im waldeyer-ring zu verstärken
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1357919B1 (de) 2001-01-16 2017-04-05 Sloan-Kettering Institute For Cancer Research Glucan zur verbesserung der therapie
BR0208901A (pt) * 2001-04-05 2004-06-29 Granada Bio Tech Sa De Cv Biopolìmeros de fosfoamida policarboxìlicos polissubstituìdos, métodos para sua produção e usos de composições derivadas destes
JP3633601B2 (ja) * 2001-04-27 2005-03-30 味の素株式会社 免疫賦活剤
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US20060073197A1 (en) * 2004-05-20 2006-04-06 Ramaekers Joseph C Encapsulated transfer factor compositions and methods of use
US20070128253A1 (en) * 2005-04-13 2007-06-07 Ramaekers Joseph C Encapsulated transfer factor compositions and methods of use
EP1393738A4 (de) * 2001-06-01 2004-11-17 Ajinomoto Kk Arzneimittel gegen diabetes
US7345023B2 (en) * 2001-08-14 2008-03-18 Valderm Aps Treatment of hyperproliferative conditions of body surfaces
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
US7048932B2 (en) * 2002-05-22 2006-05-23 The Chinese University Of Hong Kong Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
EP1545208A4 (de) * 2002-08-13 2006-04-12 Biopolymer Engineering Inc Verfahren zur verwendung von beta-glucan als strahlenschutzmittel
JP2006502167A (ja) * 2002-09-04 2006-01-19 バイオポリマー エンジニアリング，インコーポレイテッド 全グルカン粒子および抗体を用いた癌治療
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
US7018986B2 (en) * 2002-09-20 2006-03-28 Immudyne Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
US20050026849A1 (en) * 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
US7197521B2 (en) * 2003-11-21 2007-03-27 Intel Corporation Method and system performing concurrently mark-sweep garbage collection invoking garbage collection thread to track and mark live objects in heap block using bit vector
KR100485056B1 (ko) * 2004-01-19 2005-04-22 (주)네추럴에프앤피 효모의 수용성 글루칸 올리고머를 함유하는 항 h1n2형 조류독감 바이러스제
CA2912012C (en) 2005-05-05 2018-05-29 Sensient Flavors Inc. Production of beta-glucans and mannans
ATE442153T1 (de) 2005-11-21 2009-09-15 Bioatlantis Ltd Zusammensetzungen für die verbesserung der darmgesundheit und der tierischen leistung enthaltend beta-glucans and alfa-fucans
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
FR2899815B1 (fr) * 2006-04-14 2008-07-11 Goemar Lab Sa Nouveaux medicaments pour les traitements contre les retrovirus
US20090053197A1 (en) * 2006-06-14 2009-02-26 Ramaekers Joseph C Transfer Factor Compositions and Methods
US9125874B2 (en) 2007-11-30 2015-09-08 The Ramaekers Family Trust Administration of transfer factor for improving reproductive health
US20090022799A1 (en) * 2006-10-06 2009-01-22 Shikha Pramanik Barman Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use
ES2397186T3 (es) * 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
WO2009039256A1 (en) * 2007-09-18 2009-03-26 Ramaekers Nutrition, Llc Growth factor fraction compositions and methods
WO2009070788A1 (en) * 2007-11-30 2009-06-04 The Ramaekers Family Trust Compositions and methods for enhancing fertility
US7854936B2 (en) 2008-01-14 2010-12-21 Active Organics, Inc. Anti-inflammatory hydrolysate of C. versicolor
CN101250236B (zh) * 2008-04-11 2010-09-29 武汉大学 茯苓葡聚糖磷酸酯化衍生物及其制备方法和用途
CA2760044A1 (en) 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
US20100267661A1 (en) * 2009-03-17 2010-10-21 Immudyne, Inc. Beta glucans and methods of use thereof
US20110129801A1 (en) * 2009-11-27 2011-06-02 Shikha Pramanik Barman Compositions and methods to prevent and treat dry socket post-operatively after tooth extraction surgery
CN107674129B (zh) * 2017-09-04 2020-12-15 珠海伊斯佳科技股份有限公司 裂褶多糖磷酸化衍生物及其制备方法、应用
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
US11384160B1 (en) 2021-07-30 2022-07-12 Tissue repair ltd Method of making a beta glucan compound
US11572420B1 (en) 2021-07-30 2023-02-07 Tissue repair ltd Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof
CN114014949B (zh) * 2021-11-15 2022-08-30 戚春建 一种水溶性酵母葡聚糖的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1258100B (de) * 1960-11-22 1968-01-04 Wacker Chemie Gmbh Verfahren zum Phosphorylieren hydroxylgruppenhaltiger polymerer Stoffe
US3081226A (en) * 1961-01-07 1963-03-12 Luzio Nicholas R Di Process for reducing exogenous cholesterol levels in animal organisms
US3396082A (en) * 1965-06-09 1968-08-06 Agriculture Usa Glucan production by fermentation of fleshy fungi
DE1518587A1 (de) * 1965-08-23 1969-08-14 Bloecker Dr Dipl Chem Erich Verfahren zur Herstellung von Phosphorsaeureestern von hydroxylgruppenhaltigen Polymeren
US3987166A (en) * 1970-05-13 1976-10-19 Kaken Kagaku Kabushiki Kaisha Treatment of tumors with glucan compositions in mice and rats
US3943247A (en) * 1972-05-22 1976-03-09 Kaken Kagaku Kabushiki Kaisha Treatment of bacterial infections with glucan compositions
DE2646879A1 (de) * 1975-10-21 1977-05-05 Takeda Chemical Industries Ltd Matrix aus einem in wasser unloeslichen beta-1,3-glucangel und verfahren zu ihrer herstellung
US4138479A (en) * 1975-11-07 1979-02-06 Bayer Aktiengesellschaft Process for the preparation of immunopotentiating agents from components of yeast cell wall material
JPS5385000A (en) * 1976-12-31 1978-07-26 Akira Misaki Glucan and its preparation
JPS5461112A (en) * 1977-10-24 1979-05-17 Ono Pharmaceut Co Ltd Oncostatic polysaccharide* its preparation* and oncostatic drugs containing it as an effective component
FR2447193A1 (fr) * 1979-01-25 1980-08-22 Unicler Utilisation de pichia ou d'extraits de pichia, comme medicament.
DE3071815D1 (en) * 1980-08-05 1986-12-11 Debat Lab Use of glycosylglucanes in the treatment of infections of the large intestines
US4340673A (en) * 1980-11-07 1982-07-20 Merck & Co., Inc. Process of producing modified glucans as anti-caries agent
US4614733A (en) * 1981-12-31 1986-09-30 Kureha Kagaku Kogyo Kabushiki Kaisha Polysaccharides pharmaceutical compositions and the use thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan

Also Published As

Publication number Publication date
US4818752A (en) 1989-04-04
FI871718A0 (fi) 1987-04-16
FI871718A (fi) 1987-04-16
DK198587D0 (da) 1987-04-15
DK198587A (da) 1987-06-18
US4761402A (en) 1988-08-02
JP2550332B2 (ja) 1996-11-06
AU6229686A (en) 1987-03-10
AU599045B2 (en) 1990-07-12
CA1337408C (en) 1995-10-24
KR900008442B1 (ko) 1990-11-22
NO170586C (no) 1992-11-04
US4833131A (en) 1989-05-23
KR870700355A (ko) 1987-12-28
JPS63500805A (ja) 1988-03-24
US4739046A (en) 1988-04-19
EP0232405A4 (de) 1989-04-27
FI88109B (fi) 1992-12-31
EP0232405B1 (de) 1992-01-15
NO871603L (no) 1987-06-15
US4877777A (en) 1989-10-31
NO170586B (no) 1992-07-27
ATE71528T1 (de) 1992-02-15
NO871603D0 (no) 1987-04-15
FI88109C (fi) 1993-04-13
EP0232405A1 (de) 1987-08-19
WO1987001037A1 (en) 1987-02-26

Similar Documents

Publication Publication Date Title
DE3683479D1 (de) Loesliches phosphoryliertes glukan.
NO941581L (no) Enzymbehandling av glukaner
AU554443B2 (en) 4-aminosalicylic acid as an anti-inflammatory agent
PL322015A1 (en) Derivatives of hydroxylamine useful as compounds enhancing production of accompanying molecular protein and ethod of obtaining them
WO1991017773A3 (de) Neue protein-polykation-konjugate
UA34419C2 (uk) Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин
AU5486080A (en) Antineoplastic deterpene derivatives
CA2053121A1 (en) Pharmaceutical preparation based on lys-plasminogen
IT8620691A0 (it) Procedimento di deprotezione di esteri ed eteri allilici, in particolare di derivati di carbapenem.
IE35177B1 (en) Improvements in or relating to uracil derivatives
IL75133A0 (en) Derivatives of glycerophosphocholine and glycerophosphoethanolamine,their preparation and their use
ATE79035T1 (de) Calcium- und magnesiumkomplexe von phytohaemagglutinin-polyheteroglykanen, ihre herstellung und pharmazeutische zubereitungen.
HUT60458A (en) Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
FR2455893A1 (fr) Polysaccharides physiologiquement actifs, leur preparation et leurs applications
GR3001559T3 (en) Polyoxygenated labdane derivatives, process for their preparation and their use as medicaments
NO893135L (no) Fremgangsmaate for fremstilling av n-2,3-butadienyl tri- og tetraaminoalkanderivater.
Sułkowska-Ziaja et al. Biologically active compounds of fungal origin displaying antitumor activity
EP0132359A3 (de) Natürliches menschliches Interleukin-2 und seine Herstellung
WO2023169554A8 (zh) 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
刘全宏 et al. A Preliminary Study of Killing Effect of Ultrasound Irritated HpD on S180 Tumour Cells
Madoc-Jones et al. New cesium tables for rapid calculation of intracavitary dose to the vagina
IT7829926A0 (it) Riduzioni delle perdite frontali nei pannelli solari piani o ad altre forme.
JPS57131723A (en) Enzymatic activity inhibiting agent
IE33322L (en) Vaccine manufacture
AU648046B2 (en) Treatment of breast cancer with antigestagens

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee